James Yates
Manchester Royal Infirmary(GB)
Publications by Year
Research Areas
PI3K/AKT/mTOR signaling in cancer, Mathematical Biology Tumor Growth, PARP inhibition in cancer therapy, Lung Cancer Treatments and Mutations, Pharmacogenetics and Drug Metabolism
Most-Cited Works
- → Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity(2016)707 cited
- → Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background(2012)457 cited
- → Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent(2018)321 cited
- → Preclinical Comparison of the Blood–brain barrier Permeability of Osimertinib with Other EGFR TKIs(2020)221 cited
- → PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: Comparative assessement of prediction methods of human clearance(2011)198 cited
- → PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: Prediction of plasma concentration–time profiles in human by using the physiologically‐based pharmacokinetic modeling approach